LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim & LEO Pharma partner to commercialize and further develop Spevigo: Ingelheim, Germany Wednesday, July 16, 2025, 15:00 Hrs [IST] Boehringer Ingelheim, a biopha ...

Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

LEO Pharma acquires global rights to Spevigo for $105M, boosting its dermatology pipeline and expanding access for patients ...

German family-owned pharma major Boehringer Ingelheim and Denmark’s LEO Pharma today announced an exclusive global license ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

LEO is claiming global commercial rights to Spevigo for GPP, but will also collaborate with Boehringer on potential follow-up ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...